<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        124-9-16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VOLTAREN SUPP 12.5 MG.
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DICLOFENAC SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Rectal use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Suppository
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        12.7
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DELPHARM HUNINGUE S.A.S." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DELPHARM HUNINGUE S.A.S.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AB05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Diclofenac sodium, the active ingredient in Voltaren Suppositories, is one of a group of medicines</p><p>called non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs reduce pain and inflammation.</p><p>&bull; Voltaren Suppositories relieve pain, reduce swelling and ease inflammation in conditions</p><p>affecting the joints, muscles and tendons including:</p><p>- Rheumatoid arthritis, osteoarthritis, acute gout, ankylosing spondylitis</p><p>- Backache, sprains and strains, soft tissue sports injuries, frozen shoulder, dislocations and</p><p>fractures</p><p>- Tendonitis, tenosynovitis, bursitis.</p><p>&bull; They are also used to treat pain and inflammation associated with dental and minor surgery.</p><p>&bull; In children aged 1 to 12 Voltaren Suppositories 12.5 mg are used to treat juvenile chronic</p><p>arthritis.</p><p>&bull; In children aged over 6 they can also be used alone, or in combination with other painkillers, for the short term treatment of any pain experienced after an operation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not use </strong><strong>Voltaren Suppositories</strong></p><p><strong>Some people MUST NOT use Voltaren Suppositories. Talk to your doctor if:</strong></p><p>&bull; you think you may be allergic to diclofenac sodium, aspirin, ibuprofen or any other</p><p>NSAID, or to any of the other ingredients of Voltaren Suppositories. (These are listed at</p><p>the end of the leaflet.) Signs of a hypersensitivity reaction include swelling of the face and</p><p>mouth (angioedema), breathing problems, chest pain, runny nose, skin rash or any other</p><p>allergic type reaction</p><p>&bull; you have now, or have ever had, a stomach (gastric) or duodenal (peptic) ulcer, or</p><p>bleeding in the digestive tract (this can include blood in vomit, bleeding when emptying</p><p>bowels, fresh blood in faeces or black, tarry faeces)</p><p>&bull; you have had stomach or bowel problems after you have taken other NSAIDs</p><p>&bull; you have heart, kidney or liver failure</p><p>&bull; if you have established heart disease and/or cerebrovascular disease e.g. if you have had a</p><p>heart attack, stroke, mini-stroke (TIA) or blockages to blood vessels to the heart or brain</p><p>or an operation to clear or bypass blockages</p><p>&bull; if you have or have had problems with your blood circulation (peripheral arterial disease)</p><p>&bull; you are more than six months pregnant</p><p>&bull; you suffer from ineffectual straining to empty the bowels, diarrhoea or rectal bleeding</p><p>&nbsp;</p><p><strong>b. Take special care with </strong><strong>Voltaren Suppositories</strong></p><p><strong>You should also ask yourself these questions before using Voltaren Suppositories:</strong></p><p>&bull; Do you suffer from any stomach or bowel disorders including ulcerative colitis or Crohn&#39;s</p><p>disease?</p><p>&bull; Do you have kidney or liver problems, or are you elderly?</p><p>&bull; Do you have a condition called porphyria?</p><p>&bull; Do you suffer from any blood or bleeding disorder? If you do, your doctor may ask you</p><p>to go for regular check-ups while you are using these suppositories.</p><p>&bull; Have you ever had asthma?</p><p>&bull; Are you breast-feeding?</p><p>&bull; Do you have angina, blood clots, high blood pressure, abnormally high levels of fat in</p><p>your blood (raised cholesterol or raised triglycerides)?</p><p>&bull; Do you have heart problems, or have you had a stroke, or do you think you might be at</p><p>risk of these conditions (for example, if you have high blood pressure, diabetes or high</p><p>cholesterol or are a smoker)?</p><p>&bull; Do you have diabetes?</p><p>&bull; Do you smoke?</p><p>&bull; Do you have Lupus (SLE) or any similar condition?</p><p><strong>&nbsp;</strong></p><p><strong>If the answer to any of these questions is YES, discuss your treatment with your doctor or pharmacist because Voltaren Suppositories might not be the right medicine for you.</strong></p><p><strong>&nbsp;</strong></p><p><strong>c. Taking other medicines, herbal or dietary supplements</strong></p><p>Some medicines can interfere with your treatment. Tell your doctor or pharmacist if you are</p><p>taking any of the following:</p><p>&bull; Medicines to treat diabetes</p><p>&bull; Anticoagulants (blood thinning tablets like warfarin)</p><p>&bull; Diuretics (water tablets)</p><p>&bull; Lithium (used to treat some mental problems)</p><p>&bull; Methotrexate (for some inflammatory diseases and some cancers)</p><p>&bull; Ciclosporin and tacrolimus (used to treat some inflammatory diseases and after</p><p>transplants)</p><p>&bull; Trimethoprim (a medicine used to prevent or treat urinary tract infections)</p><p>&bull; Quinolone antibiotics (for infections)</p><p>&bull; Any other NSAID or COX-2 (cyclo-oxgenase-2) inhibitor, for example aspirin or</p><p>ibuprofen</p><p>&bull; Mifepristone (a medicine used to terminate pregnancy)</p><p>&bull; Cardiac glycosides (for example digoxin), used to treat heart problems</p><p>&bull; Medicines known as SSRIs used to treat depression</p><p>&bull; Oral steroids (an anti-inflammatory drug)</p><p>&bull; Medicines used to treat heart conditions or high blood pressure, for example betablockers</p><p>or ACE inhibitors.</p><p>&bull; Voriconazole (a medicine used to treat fungal infections).</p><p>&bull; Phenytoin (a medicine used to treat seizures)</p><p>&bull; Colestipol/cholestyramine (used to lower cholesterol)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zidovudine.</p><p>&nbsp;</p><p>Always tell your doctor or pharmacist about all the medicines you are taking. <em>This means</em></p><p><em>medicines you have bought yourself as well as medicines on prescription from your doctor.</em></p><p><strong>&nbsp;</strong></p><p><strong>d. Pregnancy and breast-feeding</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Voltarol Suppositories if you are in the last 3 months of pregnancy as it could harm your unborn child or cause problems at delivery. It can cause kidney and heart problems in your unborn baby. It may affect your and your baby&rsquo;s tendency to bleed and cause labour to be later or longer than expected. You should not use Voltarol Suppositories during the first 6 months of pregnancy unless absolutely necessary and advised by your doctor. If you need treatment during this period or while you are trying to get pregnant, the lowest dose for the shortest time possible should be used. If used for more than a few days from 20 weeks of pregnancy onward, Voltarol Suppositories can cause kidney problems in your unborn baby that may lead to low levels of amniotic fluid that surrounds the baby (oligohydramnios) or narrowing of a blood vessel (ductus arteriosus) in the heart of the baby. If you need treatment for longer than a few days, your doctor may recommend additional monitoring.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are you trying for a baby? Using Voltaren Suppositories may make it more difficult to conceive. You should talk to your doctor if you are planning to become pregnant, or if you have problems getting pregnant.</p><p>&nbsp;</p><p><strong>e. </strong><strong>Driving and using machines</strong></p><p>Very occasionally people have reported that Voltaren Suppositories have made them feel dizzy, tired or sleepy. Problems with eyesight have also been reported. If you are affected in this way, you should not drive or operate machinery.</p><p><strong>&nbsp;</strong></p><p><strong>Other special warnings</strong></p><p>&bull; You should take the lowest dose of Voltaren for the shortest possible time, particularly if you</p><p>are underweight or elderly.</p><p>&bull; There is a small increased risk of heart attack or stroke when you are taking any medicine</p><p>like Voltaren. The risk is higher if you are taking high doses for a long time. Always follow</p><p>the doctor&rsquo;s instructions on how much to take and how long to take it for.</p><p>&bull; If at any time while taking Voltaren you experience any signs or symptoms of problems with</p><p>your heart or blood vessels such as chest pain, shortness of breath, weakness, or slurring of</p><p>speech, contact your doctor immediately.</p><p>&bull; Whilst you are taking these medicines your doctor may want to give you a check-up from</p><p>time to time.</p><p>&bull; If you have a history of stomach problems when you are taking NSAIDs, particularly if you</p><p>are elderly, you must tell your doctor straight away if you notice any unusual symptoms.</p><p>&bull; Because it is an anti-inflammatory medicine, Voltaren may reduce the symptoms of infection,</p><p>for example, headache and high temperature. If you feel unwell and need to see a doctor,</p><p>remember to tell him or her that you are taking Voltaren.</p><p>&bull; <strong>VOLTAREN Suppositories 50 mg and 100 mg are not suitable for children</strong>.</p><p>&bull; <strong>VOLTAREN Suppositories 12.5 mg are not used for adults</strong>.</p><p>&nbsp;</p><p>Tell your doctor if you recently had or you are going to have a surgery of the stomach or</p><p>intestinal tract before using Voltaren Suppositories, as Voltaren Suppositories can sometimes</p><p>worsen wound healing in your gut after surgery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The doctor will tell you how to use Voltaren Suppositories. Always follow his/her instructions</p><p>carefully. The dose will be on the pharmacist&rsquo;s label. Check the label carefully. If you are not sure, ask your doctor or pharmacist. Keep using the suppositories for as long as you have been told, unless you have any problems. In that case, check with your doctor.</p><p>&nbsp;</p><p>Suppositories are designed for insertion into the back passage (rectum). <strong>Never take them by</strong></p><p><strong>mouth.</strong></p><p><strong>&nbsp;</strong></p><p>The doctor may also prescribe another drug to protect the stomach to be taken at the same time,</p><p>particularly if you have had stomach problems before, or if you are elderly, or taking certain</p><p>other drugs as well</p><p>&nbsp;</p><p><strong>Adults</strong></p><p>Voltaren Suppositories are normally inserted one, two or three times a day up to a maximum</p><p>total daily dose of 150mg. The number of suppositories you need will depend on the strength</p><p>which the doctor has given you.</p><p><strong>&nbsp;</strong></p><p><strong>Elderly</strong></p><p>Your doctor may advise you to take a dose that is lower than the usual adult dose if you are</p><p>elderly. Your doctor may also want to check closely that the Voltaren Suppositories are not</p><p>affecting your stomach, particularly during the first 4 weeks that you are using the suppositories.</p><p><strong>&nbsp;</strong></p><p><strong>Children</strong></p><p><u>For the treatment of chronic juvenile arthritis in children aged 1 to 12:</u></p><p>Doses vary with age, but are usually between 1 and 3 mg/kg body weight every day divided</p><p>into 2 or 3 doses.</p><p><u>For the treatment of post-operative pain in children aged 6 and above:</u></p><p>Doses vary with age, but are usually between 1 and 2 mg/kg body weight per day divided into</p><p>2 or 3 doses for no more than 4 days.</p><p>&nbsp;</p><p>Your child&rsquo;s doctor will work out the dose that is suitable for your child and will tell you how</p><p>many Voltaren Suppositories to use and how often. Follow his/her instructions carefully. If you</p><p>are not sure about the dose, check with your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>How to insert the suppositories</strong></p><p>&bull; Empty your bowels before inserting a suppository.</p><p>&bull; Wash your hands.</p><p>&bull; Take out the strip of suppositories and tear off one along the perforation.<!--[if gte vml 1]></o:wrapblock><![endif]--><br />&bull; Then take the suppository out of the plastic wrapping by pulling back the loose end.</p><p><img alt="" width="276" height="189" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>&bull; Lie on one side with your knees pulled up towards your chest.</p><p>&bull; Gently push the suppository pointed end first into your back passage (rectum) with your<!--[if gte vml 1]></o:wrapblock><![endif]--><br />finger. Push the suppository in as far as possible as shown in the diagram.</p><p><img alt="" width="271" height="196" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>&bull; Lower your legs and, if possible, stay still for a few minutes.</p><p>&bull; If you feel as if you need to push the suppository out, try to resist this by lying still with your</p><p>buttocks pressed together. It is important to keep the suppository in the rectum to allow it to</p><p>melt and the medicine to be absorbed. Pushing the suppository high into the rectum with</p><p>your finger will help to reduce this feeling.</p><p>&bull; Wash your hands.</p><p>&nbsp;</p><p>The procedure is the same for a child. Once they have emptied their bowels, get them to lie down</p><p>on their front or side. Gently push the suppository into the child&rsquo;s back passage until it</p><p>disappears. Try and stop the child moving around for a few minutes to reduce the risk of the</p><p>suppository coming out.</p><p>&nbsp;</p><p><strong>a. if you use Voltaren suppositories more than you should</strong></p><p>You should not take more than 150 mg in one day if you are an adult. Children should not take</p><p>more than the dose that is prescribed by their doctor. If you accidentally use too many</p><p>suppositories or use them too often, tell your doctor or go to your nearest casualty department</p><p>straight away.</p><p>&nbsp;</p><p><strong>b. if you forget to use Voltaren Suppository</strong></p><p>If you forget to use a suppository, do not worry. Use one as soon as you remember. If it is nearly</p><p>time for your next dose though, just take the next dose and forget about the one you missed. Do</p><p>not double up the next dose to make up for the one you missed. Do not insert 2 suppositories at</p><p>the same time. The total dose should not be more than 150 mg each day if you are an adult.</p><p>Children should not take more than the dose that is prescribed by their doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Voltaren Suppositories are suitable for most people, but, like all medicines, they can sometimes</p><p>cause side effects. Side effects may be minimised by using the lowest effective dose for the shortest</p><p>duration necessary.</p><p>&nbsp;</p><p><strong><u>Some side effects can be serious</u></strong></p><p><strong>Stop using the suppositories and tell your doctor straight away if you notice:</strong></p><p>&bull; Sudden and crushing chest pain (signs of myocardial infarction or heart attack)</p><p>&bull; Breathlessness, difficulty breathing when lying down, swelling of the feet or legs (signs of</p><p>heart failure)</p><p>&bull; Sudden weakness or numbness in the face, arm or leg especially on one side of the body;</p><p>sudden loss or disturbance of vision; sudden difficulty in speaking or ability to understand</p><p>speech; sudden migraine-like headaches which happen for the first time, with or without</p><p>disturbed vision. These symptoms can be an early sign of a stroke</p><p>&bull; Stomach pain, indigestion, heartburn, wind, nausea (feeling sick) or vomiting (being sick)</p><p>&bull; Any sign of bleeding in the stomach or intestine, for example, when emptying your bowels,</p><p>blood in vomit or black, tarry faeces</p><p>&bull; Allergic reactions which can include skin rash, itching, bruising, painful red areas, peeling or</p><p>blistering</p><p>&bull; Wheezing or shortness of breath (bronchospasm)</p><p>&bull; Swollen face, lips, hands or fingers</p><p>&bull; Yellowing of your skin or the whites of your eyes</p><p>&bull; Persistent sore throat or high temperature</p><p>&bull; An unexpected change in the amount of urine produced and/or its appearance.</p><p>&bull; Mild cramping and tenderness of the abdomen, starting shortly after the start of the treatment</p><p>with Voltaren Suppositories and followed by rectal bleeding or bloody diarrhoea usually</p><p>within 24 hours of the onset of abdominal pain.</p><p>&bull; Chest pain, which can be a sign of a potentially serious allergic reaction called Kounis</p><p>syndrome.</p><p>&nbsp;</p><p>If you notice that you are bruising more easily than usual or have frequent sore throats or</p><p>infections, tell your doctor.</p><p>&nbsp;</p><p>Voltaren Suppositories may also occasionally cause itching or burning in your back passage or</p><p>make any haemorrhoids (piles) worse.</p><p>&nbsp;</p><p><strong><u>The side effects listed below have also been reported.</u></strong></p><p><strong>Common side effects </strong><strong><em>(These may affect between 1 and 10 in every 100 patients):</em></strong></p><p>&bull; Stomach pain, heartburn , nausea, vomiting, diarrhoea, indigestion, wind, loss of appetite</p><p>&bull; Headache, dizziness, vertigo</p><p>&bull; Skin rash or spots</p><p>&bull; Raised levels of liver enzymes in the blood</p><p>&bull; Irritation where the suppository is inserted</p><p>&nbsp;</p><p><strong>Uncommon side effects </strong><strong><em>(these may affect between 1 and 10 in every 1000 patients):</em></strong></p><p>&bull; Fast or irregular heart beat (palpitations), chest pain, heart disorders, including heart attack or</p><p>breathlessness, difficulty breathing when lying down, or swelling of the feet or legs (signs of</p><p>heart failure), especially if you have been taking a higher dose (150 mg per day) for a long</p><p>period of time.</p><p>&nbsp;</p><p><strong>Rare side effects </strong><strong><em>(These may affect between 1 in every 1000 to 1 in every 10,000 patients):</em></strong></p><p>&bull; Stomach ulcers or bleeding (there have been very rare reported cases resulting in death,</p><p>particularly in the elderly)</p><p>&bull; Gastritis (inflammation, irritation or swelling of the stomach lining)</p><p>&bull; Vomiting blood</p><p>&bull; Diarrhoea with blood in it or bleeding from the back passage</p><p>&bull; Black, tarry faeces or stools</p><p>&bull; Drowsiness, tiredness</p><p>&bull; Skin rash and itching</p><p>&bull; Fluid retention, symptoms of which include swollen ankles</p><p>&bull; Liver function disorders, including hepatitis and jaundice</p><p>&bull; Asthma (symptoms may include wheezing, breathlessness, coughing and a tightness across the</p><p>chest).</p><p>&nbsp;</p><p><strong>Very rare side effects </strong><strong><em>(These may affect less than 1 in every 10,000 patients):</em></strong></p><p><u>Effects on the nervous system:</u></p><p>Inflammation of the lining of the brain (meningitis), tingling or numbness in the fingers, tremor,</p><p>visual disturbances such as blurred or double vision, taste changes, hearing loss or impairment,</p><p>tinnitus (ringing in the ears), sleeplessness, nightmares, mood changes, depression, anxiety,</p><p>irritability, mental disorders, disorientation and loss of memory, fits, headaches together with a</p><p>dislike of bright lights, fever and a stiff neck.</p><p>&nbsp;</p><p><u>Effects on the stomach and digestive system:</u></p><p>Constipation, inflammation of the tongue, mouth ulcers, inflammation of the inside of the mouth</p><p>or lips, lower gut disorders (including inflammation of the colon, or worsening of ulcerative colitis</p><p>or Crohn&rsquo;s disease), inflammation of the pancreas.</p><p>&nbsp;</p><p><u>Effects on the chest or blood:</u></p><p>Hypertension (high blood pressure), hypotension (low blood pressure, symptoms of which may</p><p>include faintness, giddiness or light headedness), inflammation of blood vessels (vasculitis),</p><p>inflammation of the lung (pneumonitis), blood disorders (including anaemia).</p><p>&nbsp;</p><p><u>Effects on the liver or kidneys:</u></p><p>Kidney or severe liver disorders including liver failure, presence of blood or protein in the urine.</p><p>&nbsp;</p><p><u>Effects on skin or hair:</u></p><p>Facial swelling, serious skin rashes including Stevens-Johnson syndrome, Lyell&rsquo;s syndrome and</p><p>other skin rashes which may be made worse by exposure to sunlight.</p><p>Hair loss.</p><p>&nbsp;</p><p><u>Effects on the reproductive system:</u></p><p>Impotence.</p><p><strong>&nbsp;</strong></p><p><strong>Other side effects that have also been reported with unknown frequency include:</strong></p><p>Throat disorders, confusion, hallucinations, malaise (general feeling of discomfort), inflammation</p><p>of the nerves in the eye, disturbances of sensation.</p><p><strong>&nbsp;</strong></p><p><strong>Do not be alarmed by this list - most people use Voltaren Suppositories without any problems.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk your doctor or pharmacist. This includes any possible side effects</p><p>not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Store in a dry place, below 30&deg;C. Keep the suppositories in their original pack.</p><p>&bull; Keep out of the reach and sight of children.</p><p>&bull; Do not use the suppositories after the expiry date which is printed on the outside of the pack.</p><p>&bull; If your doctor tells you to stop using them, please take any unused suppositories back to your pharmacist to be destroyed. Do not throw them away with your normal household water or waste. This will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Voltaren Suppository came in concetrations of 12.5, 50, and 100 mg with the active ingredient, diclofenac sodium in a hard, fatty suppository base.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Voltaren Suppository 12.5, 50 and 100 mg are torpedo-shaped suppositories with smooth
surface; color: white to yellowish.
Voltaren Suppository 12.5, 50 mg: They come in foil packs of 10.
Voltaren Suppository 100 mg: They come in foil packs of 5.
The pack size maybe different in your country.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                11/ 2022

e. To report any side effect(s):
• Saudi Arabia
The National Pharmacovigilance Centre (NPC):
o Fax: +966-11-205-7662
o SFDA call center: 19999
o E-mail: npc.drug@sfda.gov.sa
o Website: https://ade.sfda.gov.sa 

Patient Safety Department Novartis Consulting AG - Saudi Arabia:
o Toll Free Number: 8001240078
o Phone: +966112658100 
o Fax: +966112658107
o Email: adverse.events@novartis.com  

•    Other GCC States:
-  Please contact the relevant competent authority.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يعتبر ديكلوفيناك الصوديوم، هو المادة الفعالة في عقار فولتارين تحاميل، وهو واحد من مجموعة أدوية تُسَمَّى مضادات الالتهاب غير الستيرويدية.&nbsp; وتعمل مضادات الالتهاب غير الستيرويدية على تقليل الألم والالتهاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تعمل فولتارين تحاميل على تخفيف الألم وتقليل التورم وتخفيف الالتهاب في الحالات التي تصيب المفاصل والعضلات والأوتار بما في ذلك:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل الروماتويدي، هشاشة العظام، النقرس الحاد، التهاب الفقار المقسط.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام الظهر، الالتواء، الإجهاد، الإصابات الرياضية للأنسجة اللينة، الكتف المتجمد والخلع والكسور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوتار، التهاب الوتر المفصلي، التهاب كيسي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كما أنها تستخدم لعلاج الآلام والالتهابات المصاحبة لجراحة الأسنان والجراحة البسيطة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في الأطفال الذين تزيد أعمارهم عن 6 سنوات، يمكن أيضًا استخدامها بمفردها، أو استخدامها مع مسكنات أخرى، للعلاج قصير الأمد لأي ألم يعانى منه بعد العملية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>موانع استعمال </strong><strong>فولتارين تحاميل</strong></p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong>بعض الأشخاص يجب عليهم عدم استعمال فولتارين تحاميل ، تحدث إلى طبيبك إذا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعتقد أنك قد تكون مصابًا بالحساسية تجاه ديكلوفيناك الصوديوم أو الأسبرين أو الإيبوبروفين أو أي مضادات الالتهاب غير السترويدية الأخرى، أو لأي من المكنات الأخرى لفولتارين تحاميل. (مذكورة في نهاية النشرة). علامات تفاعل فرط الحساسية تشمل تورم الوجه والفم (وذمة وعائية)، مشاكل في التنفس، ألم في الصدر، سيلان الأنف، طفح جلدي أو أي نوع آخر من ردود الفعل التحسسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك الآن، أو سبق أن عانيت من قرحة في المعدة (المعدي) أو الاثني عشر (الهضمي)، أو نزيف في الجهاز الهضمي (يمكن أن يشمل ذلك الدم في القيء، والنزيف عند إفراغ الأمعاء، والدم الطازج في البراز أو البراز الأسود والداكن).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من آلام في المعدة أو في الأمعاء عند تناول مضادات الالتهاب غير الستيرويدية الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فشل في الكلى أو الكبد أو قصور عضلة القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض في القلب و/ أو مرض في الأوعية الدموية الدماغية، مثل إذا كنت قد أصبت بنوبة قلبية أو سكتة دمغية أو سكتة دماغية صغيرة (TIA) أو انسداد الأوعية الدموية للقلب أو الدماغ أو عملية لإزالة الانسدادات أو تجاوزها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل في الدورة الدموية (مرض الشرايين المحيطية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حامل لأكثر من ستة أشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من إجهاد غير فعال لتفريغ الأمعاء أو الإسهال أو نزيف المستقيم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ب&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; <strong>الاحتياطات عند استعمال </strong><strong>فولتارين تحاميل</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب أن تسأل نفسك الأسئلة التالية قبل استعمال فولتارين تحاميل:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل تعاني من أية اضطرابات بالمعدة أو الأمعاء بما في ذلك التهاب القولون التقرحي أو مرض كرون؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل تعاني من مشاكل بالكلى أو الكبد؟ أو هل أنت من كبار السن؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل لديك حالة تُسمى البُرْفيرِيَّة؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل تعاني من أي اضطراب بالدَّم أو النزيف؟ إذا تعرضت لذلك، فقد يطلب منك طبيبك القيام بإجراء فحوصات منتظمة أثناء استخدامك لهذه التحاميل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل عانيت من قبل من مرض الربو؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل تمارسين الرضاعة الطبيعية؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل تعاني من الذبحة الصدرية، تجلط الدَّم، ارتفاع ضغط الدَّم، ارتفاع مستوى الكوليسترول أو ارتفاع مستوى الدهون الثلاثية؟</p><ul><li dir="RTL">هل تعاني من مشاكل في القلب، أو تعرضت من قبل لسكتة دماغية؟ أو هل تظن أنك قد تكون معرضًا لخطر الإصابة بهذه الحالات (على سبيل المثال: إذا كنت تعاني من ارتفاع ضغط الدَّم، أو مرض السُّكَّرِيّ، أو ارتفاع الكوليسترول أو كنت مدخنًا)؟</li><li dir="RTL">هل تعاني من مرض السُّكَّرِيّ؟</li><li dir="RTL">هل أنت مدخن؟</li><li dir="RTL">هل تعاني من مرض الذئبة الحمراء (SLE) أو أي حالة مرضية مشابهة؟</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كانت الإجابة على أي من هذه الأسئلة بنعم، فقم بمناقشة علاجك مع طبيبك أو الصيدلي؛ لأنَّ فولتارين تحاميل قد لا يكون الدَّواء المناسب لك.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج. التداخلات الدوائية من أخذ فولتارين تحاميل مع أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">يمكن أن تتداخل بعض الأدوية مع علاجك.&nbsp; أخبر طبيبك أو الصيدلي إذا كنت تتناول أيًّا من الأدوية التَّالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج مرض السُّكَّرِي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات التجلط (أقراص سيولة الدَّم مثل: وارفارين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مدرات البول (أقراص الماء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الليثيوم (يُستخدم لعلاج بعض المشاكل الذهنية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثوتريكسات (لعلاج بعض الأمراض الالتهابية وبعض السرطانات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين وتاكروليمس (يُستخدمان لعلاج بعض الأمراض الالتهابية وبعد عمليات زرع الأعضاء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ترايميثوبريم (دواء يستَخدَم للوقاية من عدوى المسالك البولية أو لعلاجها).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات البكتيريا من نوع الكينولون (لعلاج العدوى).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى المضادة للالتهاب أو المانعة لمستقبل COX-2 مثل الأسبرين أو إيبوبروفين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميفيبريستون (دواء يُستخدم لإجهاض الحمل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجليكوسيدات القلبية (مثل: ديجوكسين)، تستخدم لعلاج مشاكل القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تعرف باسم مثبطات إعادة امتصاص السيروتونين الانتقائية والتي تستخدَم لعلاج الاكتئاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الستيرويدات التي تستخدم عن طريق الفم (أحد مضادات الالتهاب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات ACE أو حاصرات البيتا (فئات من الأدوية تستعمل لعلاج ضغط الدم لأو لأمراض القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فوريكونازول (دواء يُستخدم لعلاج العدوى الفطرية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين (دواء يُستخدم لعلاج النوبات التشنجية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كوليستيبول/ كولستيرامين (يُستخدَمان لخفض الكوليسترول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيدوفودين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي دائمًا بكل الأدوية التي تتناولها.&nbsp; <em>ويعني هذا الأدوية التي اشتريتها بنفسك والأدوية التي اشتريتها بوصفة طبية من طبيبك.</em></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>د. الحمل و الرضاعة</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدمي فولتارين تحاميل إذا كنتِ في الأشهر الثلاثة الأخيرة من الحمل لأنها قد تضر بجنينك أو تسبب مشاكل عند الولادة. يمكن أن يسبب مشاكل في الكلى والقلب لجنينك الذي لم يولد بعد. قد يؤثر على قابليتكِ ونزعة طفلك للنزيف ويتسبب في تأخر المخاض أو تأخره عن المتوقع. يجب عدم استخدام فولتارين تحاميل خلال الأشهر الستة الأولى من الحمل ما لم يكن ذلك ضروريًا للغاية ونصحك طبيبك. إذا كنتِ بحاجة إلى علاج خلال هذه الفترة أو أثناء محاولتك الحمل ، فيجب استخدام أقل جرعة لأقصر وقت ممكن. إذا تم استخدامها لأكثر من بضعة أيام من &nbsp;20أول أسبوعًا من الحمل فصاعدًا ، يمكن أن تسبب فولتارين تحاميل مشاكل في الكلى لدى طفلك الذي لم يولد بعد والتي قد تؤدي إلى انخفاض مستويات السائل الأمنيوسي الذي يحيط بالطفل (oligohydramnios) أو تضيق الأوعية الدموية (القناة الشريانية) ) في قلب الطفل. إذا كنت بحاجة إلى علاج لمدة تزيد عن بضعة أيام ، فقد يوصي طبيبك بمراقبة إضافية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل تحاولين إنجاب طفل؟&nbsp; قد يؤدي استخدام فولتارين تحاميل إلى زيادة صعوبة الحمل. يجب عليكِ إخبار طبيبكِ إذا كنتِ تخططين للحمل أو إذا كنتِ تعانين من مشاكل في الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هـ. تأثير عقار فولتارين على القيادة واستخدام الآلات</strong></p><p dir="RTL">أبلغ أشخاص بأنَّ استخدام عقار فولتارين طويل المفعول جعلهم يشعرون بالدوخة أو التَّعب أو النعاس في كثير من الأحيان.&nbsp; وتم أيضًا الإبلاغ عن حدوث مشاكل في الإبصار.&nbsp; إذا تأثرت بهذه الطريقة، فيجب عدم ممارسة القيادة أو تشغيل&nbsp; الآلات.</p><p dir="RTL">&nbsp;</p><p>تحذيرات خاصَّة أخرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض الوزن أو كنت من كبار السن، يجب عليك أن تستخدم أقل جرعة من فولتارين تحاميل في أقل مدة علاجية ممكنة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هناك خطر ضئيل متزايد للإصابة بنوبة قلبية أو سكتة دماغية عند تناول أي دواء مثل فولتارين. يكون الخطر أكبر إذا كنت تتناول جرعات عالية لفترة طويلة. اتبع دائمًا تعليمات الطبيب بشأن الجرعة التي تستعملها والمدة التي تستغرقها في العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا شعرت في أي وقت أثناء استعمال فولتارين بأي علامات أو أعر اض لمشاكل في القلب أو الأوعية الدموية مثل ألم في الصدر، أو ضيق في التنفس، أوضعف، أو تداخل في الكلام، فاتصل بطبيبك على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أثناء استعمالك لهذه الأدوية، قد يرغب طبيبك في فحصك من وقت لآخر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ سابق من الإصابة بمشاكل في المعدة أثناء تناول مضادات الالتهاب غير الستيرويدية، خاصَّة إذا كنت من كبار السن، فيجب أن تقوم بإبلاغ طبيبك فورًا إذا لاحظت حدوث أي أعراض غير معتادة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نظرًا لأنَّ عقار فولتارين أحد الأدوية المضادة للالتهاب، فقد يقلل حدوث أعراض العدوى، على سبيل المثال: الصداع وارتفاع درجة الحرارة.&nbsp; إذا شعرت بأنك لست على ما يرام وبحاجة إلى زيارة الطبيب ، فتذكر أن تخبره/ تخبرها بأنك تستخدم عقار فولتارين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فولتارين تحاميل 50 مجم و 100 مجم غير مناسبة لاستعمال الأطفال.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا يُستخدم عقار فولتارين </strong><strong>تحاميل</strong><strong> 12.5 مجم للبالغين</strong>.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">التزم بتعليمات طبيبك بكل دقة. لا تتجاوز الموصّى بها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ماهي الكمية التي ينبغي أن تأخذها من فولتارين</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيخبرك الطبيب عن كيفية استخدام فولتارين تحاميل.&nbsp; اتبع دائمًا تعليماته بعناية.&nbsp;</p><p dir="RTL">ستكون الجرعة مدونة على الملصق الخاص بالصيدلي.&nbsp; تحقق من الملصق بعناية.&nbsp; إذا لم تكن متأكدًا فاستشر طبيبك أو الصيدلي.&nbsp;</p><p dir="RTL">استمر في استخدام التحاميل للمدة التي تم إخبارك بها، ما لم تعاني من أي مشاكل.&nbsp; في تلك الحالة، يُرجى مراجعة طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">صُممت التحاميل&nbsp; للإدخال في فتحة الشرج (المستقيم).&nbsp; <strong>لا تتناولها عن طريق الفم.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد يصف لك الطبيب أيضًا دواء آخر لحماية المعدة ليتم استخدامه في نفس الوقت، خاصة إذا كنت قد عانيت من قبل من مشاكل بالمعدة، أو إذا كنت من كبار السن، أو تستخدم أيضًا بعض الأدوية الأخرى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p>البالغون</p><p dir="RTL">يتم إدخال تحاميل عقار فولتارين عادةً مرة واحدة أو مرتين أو ثلاث مرات في اليوم حتى الوصول إلى الجرعة اليومية الإجمالية القصوى البالغة 150 مجم.&nbsp; سيعتمد عدد التحاميل الذي تحتاجه على التركيز الذي أعطاك إياه الطبيب.</p><p dir="RTL">&nbsp;</p><p>كبار السن</p><p dir="RTL">قد ينصحك طبيبك باستخدام جرعة أقل من الجرعة المعتادة التي يستخدمها البالغون إذا كنت من كبار السن. قد يرغب طبيبك أيضًا في التَّحقق عن كثب من أنَّ عقار فولتارين تحاميل لا يُؤثر على معدتك، وخاصَّة خلال أول 4 أسابيع تستخدم فيها التحاميل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">ل<u>علاج التهاب المفاصل الروماتويدي اليفعي عند الأطفال من عمر 1 إلى 12 سنة:</u></p><p dir="RTL">تختلف الجرعات حسب العمر، ولكنها تتراوح عادةً بين 1 و 3 مجم / كجم من وزن الجسم كل يوم مقسمة إلى جرعتين أو ثلاث جرعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>لعلاج آلام مابعد الجراحة لدى الأطفال من سن 6 وما فوق: </u></p><p dir="RTL">تختلف الجرعات حسب العمر، ولكنها تتراوح عادةً بين 1 و 2 مجم / كجم من وزن الجسم يوميًا مقسمة إلى جرعتان أو 3 جرعات لمدة لا تزيد عن 4 أيام.</p><p dir="RTL">طبيب الأطفال سيحدد الجرعة المناسبة لطفلك وسيخبرك كم عدد فولتارين تحاميل التي يجب استخدامها وكم مرة، اتبع التعليمات بعناية إذا لم تكن متأكدًا من الجرعة، فاستشر طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية إدخال ال</strong><strong>تحاميل</strong></p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp; قم بإفراغ أمعائك قبل إدخال أحد التحاميل.</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp; اغسل يديك.</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp; قم بإخراج شريط التحاميل وانزع واحدًا عن طريق القطع على طول الثقوب.</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp; ثم قم بإخراج التحميلة من الغلاف البلاستيكي عن طريق سحب الطرف الغير المحكم للخلف.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<img src="data:image/png;base64,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" alt="" width="276" height="189" vspace="0" hspace="0" border="0" style="width:276px;height:189px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp; استلقِ على أحد الجانبين مع ثني ركبتيك إلى صدرك.</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp; قم بدفع نهاية التحميلة المشار إليها أولًا في فتحة الشرج (المستقيم) بإصبعك.&nbsp; ادفع القمع للداخل قدر الإمكان على النحو المبين في الشكل.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<img alt="" width="271" height="196" src="data:image/png;base64,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" />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اخفض ساقيك وابق ساكنًا لبضع دقائق إن أمكن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا شعرت كأنك بحاجة إلى إخراج القمع، حاول مقاومة ذلك عن طريق البقاء مستلقيًا مع الضغط على أردافك معًا.&nbsp; من الهام إبقاء القمع داخل المستقيم؛ للسماح له بالذوبان والسماح للدَّواء بالامتصاص.&nbsp; سيُساعد دفع القمع بعيدًا داخل المستقيم بإصبعك في الحد من هذا الشعور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اغسل يديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يكون الإجراء هو نفسه المتَّبع بالنسبة للطفل.&nbsp; بمجرد إفراغ أمعائه، قم بجعله مستلقيًا على بطنه أو على أحد جانبيه. قم بدفع القمع داخل فتحة الشرج لدى الطفل حتى يختفي. حاول عدم تحريك الطفل وإيقافه من الحركة لبضع دقائق؛ للحد من خطر خروج التحميلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; <strong>الجرعة الزائدة من عقار فولتارين طويل المفعول</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا يجب أن تستعمل أكثر من 150 مجم في يوم واحد إذا كنت بالغًا. يجب على الأطفال عدم استخدام جرعة أكبر من الجرعة الموصوفة لهم من قبل الطبيب. إذا استخدمت عدد كبير جدًّا من التحاميل بطريق الخطأ أو استخدمتها في كثير من الأحيان، فأخبر طبيبك، أو اذهب إلى أقرب قسم طَّوارئ لك فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ب&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; <strong>نسيان تناول الجرعة من فولتارين تحاميل</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا نسيت استخدام التحاميل، لا تقلق. قم باستخدام واحد بمجرد تذكرك. إذا كان قد حان موعد جرعتك التَّالية، فاستخدم فقط الجرعة التَّالية وتخطى الجرعة التي نسيتها. لا تقم بمضاعفة الجرعة التالية لتعويض الجرعة التي نسيتها.&nbsp; لا تقم بإدخال قمعين في نفس الوقت.&nbsp; يجب أَلَّا تتجاوز الجرعة الإجمالية 150 مجم في اليوم إذا كنت من البالغين. يجب على الأطفال عدم استخدام جرعة أكبر من الجرعة الموصوفة لهم من قبل الطبيب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يكون عقار فولتارين تحاميل مناسبًا لمعظم الأشخاص، ولكن، مثله مثل كافة الأدوية، من الممكن أحيانًا أن يُسبب آثارًا جانبية. يُمكِن الحد من الآثار الجانبيَّة باستخدام أقل جرعة فعَّالة لأقصر مدة ضرورية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>بعض الآثار الجانبية قد تكون خطيرة</u></strong></p><p dir="RTL"><strong>توقف عن استخدام ال</strong><strong>تحاميل</strong><strong> وأخبر طبيبك فورًا إذا لاحظت الآتي:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم وضيق مفاجئ في الصدر ( علامات احتشاء عضلة القلب أو النوبة القلبية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انقطاع التنفس، صعوبة التنفس عند الاستلقاء، تورم القدمين أو الساقين (علامات قصور القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف مفاجئ أو تنميل في الوجه أو الذراع أو الساق خاصة في جانب واحد من الجسم. فقدان مفاجئ أو اضطراب في الرؤية. صعوبة مفاجئة في التحدث أو القدرة على فهم الكلام، صداع مفاجئ شبيه بالصداع النصفي يحدث لأول مرة مع أو بدون اضطراب في الرؤية. يمكن أن تكون هذه الأعراض علامة مبكرة على السكتة الدماغية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألمًا بالمعدة، عسر الهضم، حموضة (حُرْقَة الفُؤاد)، ريحًا، غثيانًا (الشعور بالإعياء) أو القيء (الإعياء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي علامة على وجود نزيف في المعدة أو الأمعاء، على سبيل المثال: عند إفراغ أمعائك، وجود دم في القيء أو إخراج براز بلون أسود قطراني.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية التي من الممكن أن تشمل طفحًا جلديًّا، حكة، كدمات، مناطق مؤلمة حمراء، تقشير أو تقرحات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صفير أو ضيق التنفس (تشنُّجًا قَصَبيًّا).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه، أو الشفتين أو اليدين أو الأصابع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار بشرتك أو بياض عينيك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق المستمر أو ارتفاع درجة الحرارة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرًا غير متوقع في كمية البول الناتج و/ أو شكله.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات خفيفة وألم في البطن، تبدأ بعد فترة قصيرة من بدء العلاج بعقار فولتارين تحاميل وتكون متبوعة بنزيف في المستقيم أو إسهال مصحوب بدم، ويكون ذلك عادة خلال 24 ساعة من حدوث ألم البطن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر، والذي يمكن أن يكون علامة على رد فعل تحسسي خطير محتمل يسمى متلازمة كونس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لاحظت أنك تعاني من الكدمات بسهولة أكثر من المعتاد أو تعاني من التهاب الحلق أو الالتهاب المتكررة، أخبر طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تسبب فولتارين تحاميل أحيانًا حكة أو حرقًا في الممر الخلفي أو تزيد من سوء البواسير.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>تم أيضًا الإبلاغ عن الآثار الجانبية المذكورة</u></strong><strong><u> </u></strong><strong><u>&nbsp;أدناه.</u></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بعض </strong><strong>الآثار الجانبية الشَّائعة<em> (قد تؤثر في ما بين 1 و 10 في كل 100 مريض):</em></strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمعدة، حموضة (حُرْقَة الفُؤاد)، غثيان، قيء، إسهال، عسر الهضم، انتفاخ، فقدان الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع، دوخة، دوار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة أو طفح جلدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل في نتائج اختبارات الوظيفة الكبدية (مثلًا زيادة مستوى أنزيمات الكبد &quot;الترانسأمينيز&quot;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيُّج في موضع إدخال التحميلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بعض </strong><strong>الآثار الجانبية غير الشَّائعة<em> (قد تؤثر في ما بين 1 و 10 في كل 1000 مريض):</em></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; خفقان أو نبضات قلب متسارعة، ألم في الصدر، مشاكل في القلب، بما في ذلك نوبات قلبية أو ضيق في التنفس، صعوبة التنفس أثناء الاستلقاء، أو تورم الساق أو القدم (علامات قصور عضلة القلب)، خصوصًا عند استعمال جرعات عالية (150 مجم في اليوم الواحد) لمدة علاجية طويلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>بعض الآثار الجانبية النَّادرة ( قد تُؤثر في ما بين 1 إلى 10 في كل&nbsp; 10000 مريض): </em></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرحة أو نزيف بالمعدة (تم الإبلاغ عن حالات نادرة جدًّا أدت إلى الوفاة، وخاصَّة في المرضى من كبار السن).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة (التهاب، تهيج أو تورم بطانة المعدة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء دموي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال به دم أو نزيف من المستقيم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خروج براز أسود أو داكن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس والتعب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي وحكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس السوائل، تتضمن أعراضها تورم الكاحلين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات بوظائف الكبد، بما في ذلك التهاب الكبد واليرقان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الربو (قد تشمل الأعراض الصفير وضيق التنفس والسعال وضيق في الصدر).</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>بعض الآثار الجانبيَّة النَّادرة جدًّا<em> (قد تُؤثر في أقل من 1 في كل 10000 مريض):</em></strong></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><u>التَّأثيرات على الجهاز العصبي:</u></p><p dir="RTL">التهاب بطانة الدماغ (التهاب السحايا)، تنميل أو وخز في الأصابع، رعاش، اضطرابات بصرية مثل: ازدواج الرؤية أو عدم وضوحها، تغيرات في حاسة التذوق، فقدان حاسة السمع أو ضعفها، طنين بالأذن، عدم القدرة على النوم (أرق)، كوابيس، تغيرات في المزاج، اكتئاب، قلق، اضطرابات ذهنية، تَوَهان وفقدان الذاكرة، نوبات تشنج، صداع مصحوب بنفور من الأضواء الساطعة، حمى تيبس الرقبة.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>التَّأثيرات على المعدة والجهاز الهضمي:</u></p><p dir="RTL">إمساك، التهاب اللسان، قرح بالفم، التهاب بداخل الفم أو الشفتين، اضطرابات الأمعاء السفلية (بما في ذلك: التهاب القولون، أو تفاقم التهاب القولون التقرحي أو مرض كرون)، والتهاب البنكرياس.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>التَّأثيرات على القلب أو الصدر أو الدَّم:</u></p><p dir="RTL">ارتفاع ضغط الدَّم، انخفاض ضغط الدم (وقد تشمل أعراضه الإغماء، والدوخة أو خفة الرأس)، والتهاب الأوعية الدموية، التهاب رئوي، واضطرابات الدم ( بما في ذلك فقر الدم).</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>التَّأثيرات على الكبد أو الكُلى:</u></p><p dir="RTL">اضطرابات بالكبد أو الكُلى بما في ذلك؛ الفشل الكبدي، وجود الدم أو البروتين في البول.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>التأثيرات على الجلد أو الشعر:</u></p><p dir="RTL">تورم الوجه والطفح الجلدي الخطير بما في ذلك متلازمة ستيفنز جونسون ومتلازمة ليل والطفح الجلدية الأخرى التي قد تتفاقم بسبب التعرض لأشعة الشمس.</p><p dir="RTL">تساقط الشعر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التأثيرات على الجهاز التناسلي:</u></p><p dir="RTL">ضعف جنسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ومن الآثار الجانبية الأخرى التي تم الإبلاغ عنها أيضًا ما يلي:</strong></p><p dir="RTL">اضطرابات الحلق، ارتباك، هلوسة، توعك (شعور عام بعدم الرَّاحة)، التهاب الأعصاب في العينين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تقلق من قائمة الآثار الجانبية هذه - فمعظم الأشخاص يستخدمون عقار فولتارين </strong><strong>تحاميل</strong><strong> بدون أي مشاكل.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا ظهرت لديك أي آثار جانبية، تحدث مع طبيبك أو الصيدلي. يتضمن ذلك أي آثار جانبية محتملة غير مذكورة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ في مكان جاف، في درجة حرارة أقل من 30 درجة مئوية.&nbsp; تُحفظ التحاميل في عبوتها الأصلية.</p><p dir="RTL">يُحفظ بعيدًا عن مُتناوَل ورؤية الأطفال.</p><p dir="RTL">لا تستخدم التحاميل بعد انتهاء تاريخ الصلاحية المطبوع&nbsp; على الجزء الخارجي من العبوة.</p><p dir="RTL">إذا أخبرك طبيبك أن تتوقف عن استخدام التحاميل، فيرجى إعادة أية تحاميل غير مستخدمة إلى الصيدلي للتَّخلص منها. لا تتخلص منها عن طريق إلقائها في مياه الصرف الصحي أو المخلفات المنزلية الخاصة بك.&nbsp; سيساعد ذلك على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تتوفر التحاميل في تركيزات تحتوي على إما 12.5، 50 أو 100 مجم من المادة الفعالة، ديكلوفيناك الصوديوم في قاعدة تحاميل صلبة ودهنية.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">فولتارين تحاميل 12.50 مجم، 50 مجم و 100 مجم قمعية الشكل مع سطح أملس، ولونها أبيض مصفر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">فولتارين تحاميل 12.50 مجم و 50 مجم: تتوفر في عبوات من رقائق معدنية تحتوي على 10 تحاميل.</p><p dir="RTL">فولتارين تحاميل 100مجم: تتوفر في عبوات من رقائق معدنية تحتوي على 5 تحاميل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذه المعلومات قد تختلف في بعض الدول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            11 / 2022

هـ.  للإبلاغ عن الأعراض الجانبية : 
•	المملكة العربية السعودية

   -المركز الوطني للتيقظ والسلامة الدوائية (NPC)
الفاكس: +966-11-205-7662
مركز اتصال الهيئة السعودية للغذاء والدواء: 19999
البريد الالكتروني: npc.drug@sfda.gov.sa
الموقع الالكتروني: https://ade.sfda.gov.sa

-	شركة نوفارتس - السعودية - قسم سلامة المرضى:
الهاتف المجاني: 8001240078
الهاتف:  +966112658100
الفاكس: +966112658107
البريد الالكتروني: adverse.events@novartis.com

دول مجلس التَّعاون الخليجي الأخرى: 
- يُرجى الاتصال بسلطات الاختصاص المعنية
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Voltaren Suppositories 12.5mg						 
Voltaren Suppositories 50mg	
Voltaren Suppositories 100mg	

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The active substance is sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate (diclofenac sodium).
Each suppository contains 12.5mg diclofenac sodium Ph.Eur.

For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Suppositories. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Voltaren Suppository 50mg and 100mg:</strong></p><p><em>Adults and Elderly</em>:</p><p>Relief of all grades of pain and inflammation in a wide range of conditions, including:</p><p>(i) arthritic conditions: rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute gout,</p><p>(ii) acute musculo-skeletal disorders such as periarthritis (for example frozen shoulder), tendinitis,</p><p>tenosynovitis, bursitis,</p><p>(iii) other painful conditions resulting from trauma, including fracture, low back pain, sprains,</p><p>strains, dislocations, orthopaedic, dental and other minor surgery.</p><p><em>Children</em>: Not indicated.</p><p><strong>Voltaren suppository 12.5mg:</strong></p><p><em>Children (aged 1-12 years)</em>:</p><p>- Juvenile chronic arthritis</p><p><em>Children (aged 6 years and above):</em></p><p>- As monotherapy or as adjunct therapy with morphine or other opiates (due to its opiatesparing</p><p>effect) for the relief of acute post-operative pain.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Undesirable effects may be minimised by using the lowest effective dose for the shortest duration</p><p>necessary to control symptoms (see section 4.4 Special warnings and precautions for use).</p><p>&nbsp;</p><p>Not to be taken by mouth, as per rectal administration only.</p><p>&nbsp;</p><p>The suppositories should be inserted well into the rectum. It is recommended to insert the</p><p>suppositories after passing stools.</p><p>&nbsp;</p><p><strong>Adults</strong></p><p>75-150mg daily, in divided doses (50mg and 100mg suppositories only).</p><p>The recommended maximum daily dose of Voltaren is 150mg. This may be administered using a</p><p>combination of dosage forms, e.g. tablets and suppositories. (50mg suppositories only).</p><p>12.5 mg Suppositories are not applicable for use</p><p><strong>Special populations</strong></p><p><strong>Elderly</strong></p><p>Although the pharmacokinetics of Voltarol are not impaired to any clinically relevant extent in elderly</p><p>patients, nonsteroidal anti-inflammatory drugs should be used with particular caution in such patients</p><p>who generally are more prone to adverse reactions. In particular it is recommended that the lowest</p><p>effective dosage be used in frail elderly patients or those with a low body weight (see also Precautions)</p><p>and the patient should be monitored for GI bleeding during NSAID therapy.</p><p>12.5 mg Suppositories are not applicable for use</p><p>&nbsp;</p><p><strong>Cardiovascular disease or significant cardiovascular risk factors</strong></p><p>Voltaren is contraindicated in patients with established congestive heart failure (NYHA II-IV), ischemic</p><p>heart disease, peripheral arterial disease and/or cerebrovascular disease (see section 4.3 Contraindications).</p><p>Patients with congestive heart failure (NYHA-I) or significant risk factors for cardiovascular disease</p><p>should be treated with diclofenac only after careful consideration. Since cardiovascular risks with</p><p>diclofenac may increase with dose and duration of exposure, the lowest effective daily dose should be</p><p>used and for the shortest duration possible (see section 4.4 Special warnings and precautions for use).</p><p><strong>&nbsp;</strong></p><p><strong>Renal impairment</strong></p><p>Voltaren is contraindicated in patients with renal failure (see section 4.3 Contraindications).</p><p>No specific studies have been carried out in patients with renal impairment, therefore, no specific dose</p><p>adjustment recommendations can be made. Caution is advised when administering Voltaren to</p><p>patients with mild to moderate renal impairment (see section 4.4 Special warnings and precautions</p><p>for use).</p><p>&nbsp;</p><p><strong>Hepatic impairment</strong></p><p>Voltaren is contraindicated in patients with hepatic failure (see section 4.3 Contraindications).</p><p>&nbsp;</p><p>No specific studies have been carried out in patients with hepatic impairment, therefore, no specific</p><p>dose adjustment recommendations can be made. Caution is advised when administering diclofenac to</p><p>patients with mild to moderate hepatic impairment (see section 4.4 Special warnings and precautions</p><p>for use).</p><p>&nbsp;</p><p><strong>Paediatric population</strong></p><p>Children <em>(aged 1-12 years) </em>with juvenile chronic arthritis: 1-3mg/kg per day divided into 2 or</p><p>3 doses. (12.5mg suppositories only)</p><p>Children <em>(aged 6-12 years) </em>with acute post-operative pain: 1-2mg/kg per day in divided</p><p>doses.</p><p>Treatment of acute post-operative pain should be limited to 4 days treatment. (12.5mg</p><p>suppositories only)</p><p><em>Voltaren 50 mg suppositories:</em></p><p>Not applicable.</p><p><em>Voltaren 100 mg suppositories:</em></p><p>Not suitable for children</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance or any of the excipients.
• Active, gastric or intestinal ulcer, bleeding or perforation
• History of gastrointestinal bleeding or perforation, relating to previous NSAID therapy
• Active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven
ulceration or bleeding)
• Last trimester of pregnancy (see section 4.6 Pregnancy and lactation)
• Hepatic failure
• Renal failure
• Established congestive heart failure (NYHA II-IV), ischemic heart disease, peripheral arterial
disease and/or cerebrovascular disease.
• Like other non-steroidal anti-inflammatory drugs (NSAIDs), diclofenac is also contraindicated
in patients in whom attacks of asthma, angioedema, urticaria or acute rhinitis are precipitated by
ibuprofen, acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs.
• Proctitis

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>General</strong></p><p>Undesirable effects may be minimised by using the lowest effective dose for the shortest duration</p><p>necessary to control symptoms (see section 4.2 Posology and method of administration and GI and</p><p>cardiovascular risks below).</p><p>&nbsp;</p><p>The concomitant use of Voltaren with systemic NSAIDs including cyclooxygenase-2 selective</p><p>inhibitors should be avoided due to the absence of any evidence demonstrating synergistic benefits and</p><p>the potential for additive undesirable effects (see section 4.5 Interactions with other medicaments and</p><p>other forms of interaction).</p><p>&nbsp;</p><p>Caution is indicated in the elderly on basic medical grounds. In particular, it is recommended that the</p><p>lowest effective dose be used in frail elderly patients or those with a low body weight (see section 4.2</p><p>Posology and Method of administration).</p><p>&nbsp;</p><p>As with other nonsteroidal anti-inflammatory drugs including diclofenac, allergic reactions, including</p><p>anaphylactic/anaphylactoid reactions, can also occur without earlier exposure to the drug (see section</p><p>4.8 Undesirable effects). Hypersensitivity reactions can also progress to Kounis syndrome, a serious</p><p>allergic reaction that can result in myocardial infarction. Presenting symptoms of such reactions can</p><p>include chest pain occurring in association with an allergic reaction to diclofenac.</p><p>&nbsp;</p><p>Like other NSAIDs, diclofenac may mask the signs and symptoms of the infection due to its</p><p>pharmacodynamic properties.</p><p>&nbsp;</p><p><strong>Gastrointestinal effects:</strong></p><p>Gastrointestinal bleeding (haematemesis, melaena) ulceration or perforation which can be fatal has been</p><p>reported with all NSAIDs including diclofenac and may occur at any time during treatment, with or</p><p>without warning symptoms or a previous history of serious GI events. They generally have more serious</p><p>consequences in the elderly. If gastrointestinal bleeding or ulceration occurs in patients receiving</p><p>diclofenac, the drug should be withdrawn.</p><p>&nbsp;</p><p>As with all NSAIDs, including diclofenac, close medical surveillance is imperative and particular</p><p>caution should be exercised when prescribing diclofenac in patients with symptoms indicative of</p><p>gastrointestinal disorders, or with a history suggestive of gastric or intestinal ulceration, bleeding or</p><p>perforation (see section 4.8 Undesirable effects). The risk of GI bleeding, ulceration or perforation is</p><p>higher with increasing NSAID doses including diclofenac, and in patients with a history of ulcer,</p><p>particularly if complicated with haemorrhage or perforation.</p><p>&nbsp;</p><p>The elderly have increased frequency of adverse reactions to NSAIDs especially gastrointestinal</p><p>bleeding and perforation which may be fatal (see section 4.2 Posology and method of administration).</p><p>&nbsp;</p><p>To reduce the risk of GI toxicity in patients with a history of ulcer, particularly if complicated with</p><p>haemorrhage or perforation, and in the elderly, the treatment should be initiated and maintained at the</p><p>lowest effective dose.</p><p>&nbsp;</p><p>Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be</p><p>considered for these patients, and also for patients requiring concomitant use of medicinal products</p><p>containing low dose acetylsalicylic acid (ASA/aspirin or medicinal products likely to increase</p><p>gastrointestinal risk. (See section 4.5 Interactions with other medicaments and other forms of</p><p>interaction).</p><p>&nbsp;</p><p>Patients with a history of GI toxicity, particularly when elderly, should report any unusual abdominal</p><p>symptoms (especially GI bleeding).</p><p>&nbsp;</p><p>Caution is recommended in patients receiving concomitant medications which could increase the risk</p><p>of ulceration or bleeding, such as systemic corticosteroids, anticoagulants such as warfarin, selective</p><p>serotonin-reuptake inhibitors (SSRIs) or anti-platelet agents such as acetylsalicylic acid (see section 4.5</p><p>Interaction with other medicaments and other forms of interaction).</p><p>&nbsp;</p><p>Close medical surveillance and caution should be exercised in patients with ulcerative colitis, or with</p><p>Crohn&#39;s disease as these conditions may be exacerbated (see section 4.8 Undesirable effects).</p><p>&nbsp;</p><p>NSAIDs, including diclofenac, may be associated with increased risk of gastro-intestinal anastomotic</p><p>leak. Close medical surveillance and caution are recommended when using diclofenac after gastrointestinal surgery.</p><p>&nbsp;</p><p><strong>Hepatic effects:</strong></p><p>Close medical surveillance is required when prescribing Voltaren to patients with impairment of hepatic</p><p>function as their condition may be exacerbated.</p><p>&nbsp;</p><p>As with other NSAIDs, including diclofenac, values of one or more liver enzymes may increase. During</p><p>prolonged treatment with Diclofenac, regular monitoring of hepatic function is indicated as a</p><p>precautionary measure.</p><p>&nbsp;</p><p>If abnormal liver function tests persist or worsen, clinical signs or symptoms consistent with liver</p><p>disease develop or if other manifestations occur (eosinophilia, rash), Voltaren should be discontinued.</p><p>&nbsp;</p><p>Hepatitis may occur with diclofenac without prodromal symptoms.</p><p>&nbsp;</p><p>Caution is called for when using diclofenac in patients with hepatic porphyria, since it may trigger an</p><p>attack.</p><p>&nbsp;</p><p><strong>Renal effects</strong>:</p><p>As fluid retention and oedema have been reported in association with NSAIDs therapy, including</p><p>diclofenac, particular caution is called for in patients with impaired cardiac or renal function, history of</p><p>hypertension, the elderly, patients receiving concomitant treatment with diuretics or medicinal products</p><p>that can significantly impact renal function, and those patients with substantial extracellular volume</p><p>depletion from any cause, e.g. before or after major surgery (see section 4.3 Contraindications).</p><p>Monitoring of renal function is recommended as a precautionary measure when using diclofenac in</p><p>such cases. Discontinuation therapy is usually followed by recovery to the pre-treatment state.</p><p>&nbsp;</p><p><strong>Skin effects</strong>:</p><p>Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome</p><p>and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs,</p><p>including Voltaren (see section 4.8 Undesirable effects). Patients appear to be at the highest risk of</p><p>these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases</p><p>within the first month of treatment. Voltaren should be discontinued at the first appearance of skin rash,</p><p>mucosal lesions or any other signs of hypersensitivity.</p><p>&nbsp;</p><p><strong>SLE and mixed connective tissue disease:</strong></p><p>In patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders there may</p><p>be an increased risk of aseptic meningitis (see section 4.8 Undesirable effects).</p><p>&nbsp;</p><p><strong>Cardiovascular and cerebrovascular effects:</strong></p><p>Patients with congestive heart failure (NYHA-I) or patients with significant risk factors for</p><p>cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be</p><p>treated with diclofenac after careful consideration.</p><p>&nbsp;</p><p>As the cardiovascular risks of diclofenac may increase with dose and duration of exposure, the shortest</p><p>duration possible and the lowest effective daily dose should be used. The patient&rsquo;s need for symptomatic</p><p>relief and response to therapy should be re-evaluated periodically.</p><p>&nbsp;</p><p>Appropriate monitoring and advice are required for patients with a history of hypertension and</p><p>congestive heart failure (NYHA-I) as fluid retention and oedema have been reported in association with</p><p>NSAID therapy, including diclofenac.</p><p>&nbsp;</p><p>Clinical trial and epidemiological data consistently point towards increased risk of arterial thrombotic</p><p>events (for example myocardial infarction or stroke) associated with the use of diclofenac, particularly</p><p>at high dose (150mg daily) and in long term treatment.</p><p>&nbsp;</p><p>Patients should remain alert for the signs and symptoms of serious arteriothrombotic events (e.g. chest</p><p>pain, shortness of breath, weakness, slurring of speech), which can occur without warnings. Patients</p><p>should be instructed to see a physician immediately in case of such an event.</p><p>&nbsp;</p><p><strong>Haematological effects:</strong></p><p>During prolonged treatment with diclofenac, as with other NSAIDs, monitoring of the blood count is</p><p>recommended.</p><p>&nbsp;</p><p>Voltaren may reversibly inhibit platelet aggregation (see anticoagulants in section 4.5 Interaction with</p><p>other medicaments and other forms of interactions). Patients with defects of haemostasis, bleeding</p><p>diathesis or haematological abnormalities should be carefully monitored.</p><p>&nbsp;</p><p><strong>Pre-existing asthma:</strong></p><p>In patients with asthma, seasonal allergic rhinitis, swelling of the nasal mucosa (i.e. nasal polyps),</p><p>chronic obstructive pulmonary diseases or chronic infections of the respiratory tract (especially if linked</p><p>to allergic rhinitis-like symptoms), reactions on NSAIDs like asthma exacerbations (so called</p><p>intolerance to analgesics / analgesics asthma), Quincke&rsquo;s oedema or urticaria are more frequent than in</p><p>other patients. Therefore, special precaution is recommended in such patients (readiness for</p><p>emergency). This is applicable as well for patients who are allergic to other substances, e.g. with skin</p><p>reactions, pruritus or urticaria.</p><p>&nbsp;</p><p>Like other drugs that inhibit prostaglandin synthetase activity, diclofenac sodium and other NSAIDs</p><p>can precipitate bronchospasm if administered to patients suffering from, or with a previous history of</p><p>bronchial asthma.</p><p>&nbsp;</p><p><strong>Female fertility:</strong></p><p>The use of Voltaren may impair female fertility and is not recommended in women attempting to</p><p>conceive. In women who may have difficulties conceiving or who are undergoing investigation of</p><p>infertility, withdrawal of Voltaren should be considered (see section 4.6 Pregnancy and Lactation).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following interactions include those observed with diclofenac gastro-resistant tablets and/or other</p><p>pharmaceutical forms of diclofenac.</p><p>&nbsp;</p><p><strong>Lithium: </strong>If used concomitantly, Voltaren may increase plasma concentrations of lithium Monitoring</p><p>of the serum lithium level is recommended.</p><p><strong>Digoxin: </strong>If used concomitantly, Voltaren may raise plasma concentrations of digoxin. Monitoring of</p><p>the serum digoxin level is recommended.</p><p>&nbsp;</p><p><strong>Diuretics and antihypertensive agents: </strong>Like other NSAIDs, concomitant use of Voltaren with</p><p>diuretics and antihypertensive agents (e.g. beta-blockers, angiotensin converting enzyme (ACE)</p><p>inhibitors may cause a decrease in their antihypertensive effect via inhibition of vasodilatory</p><p>prostaglandin synthesis.</p><p>&nbsp;</p><p>Therefore, the combination should be administered with caution and patients, especially the elderly,</p><p>should have their blood pressure periodically monitored. Patients should be adequately hydrated and</p><p>consideration should be given to monitoring of renal function after initiation of concomitant therapy</p><p>periodically thereafter, particularly for diuretics and ACE inhibitors due to the increased risk of</p><p>nephrotoxicity.</p><p>&nbsp;</p><p><strong>Drugs known to cause hyperkalemia</strong>: Concomitant treatment with potassium-sparing diuretics,</p><p>ciclosporin, tacrolimus or trimethoprim may be associated with increased serum potassium levels,</p><p>which should therefore be monitored frequently (see section 4.4 Special warnings and precautions for</p><p>use).</p><p>&nbsp;</p><p><strong>Anticoagulants and anti-platelet agents: </strong>Caution is recommended since concomitant administration</p><p>could increase the risk of bleeding (see section 4.4 Special warnings and precautions for use). Although</p><p>clinical investigations do not appear to indicate that diclofenac has an influence on the effect of</p><p>anticoagulants, there are reports of an increased risk of haemorrhage in patients receiving diclofenac</p><p>and anticoagulant concomitantly (see section 4.4 Special warnings and precautions for use). Therefore,</p><p>to be certain that no change in anticoagulant dosage is required, close monitoring of such patients is</p><p>required. As with other nonsteroidal anti-inflammatory agents, diclofenac in a high dose can reversibly</p><p>inhibit platelet aggregation.</p><p>&nbsp;</p><p><strong>Other NSAIDs including cyclooxygenase-2 selective inhibitors and corticosteroids: </strong>Coadministration</p><p>of diclofenac with other systemic NSAIDs or corticosteroids may increase the risk of</p><p>gastrointestinal bleeding or ulceration. Avoid concomitant use of two or more NSAIDs (see section 4.4</p><p>Special warnings and precautions for use).</p><p>&nbsp;</p><p><strong>Selective serotonin reuptake inhibitors (SSRIs): </strong>Concomitant administration of SSRI&rsquo;s may increase</p><p>the risk of gastrointestinal bleeding (see section 4.4 Special warnings and precautions for use).</p><p>&nbsp;</p><p><strong>Antidiabetics: </strong>Clinical studies have shown that Voltaren can be given together with oral antidiabetic</p><p>agents without influencing their clinical effect. However there have been isolated reports of</p><p>hypoglycaemic and hyperglycaemic effects necessitating changes in the dosage of the antidiabetic</p><p>agents during treatment with diclofenac. For this reason, monitoring of the blood glucose level is</p><p>recommended as a precautionary measure during concomitant therapy.</p><p>&nbsp;</p><p><strong>Methotrexate: </strong>Diclofenac can inhibit the tubular renal clearance of methotrexate hereby increasing</p><p>methotrexate levels. Caution is recommended when NSAIDs, including diclofenac, are administered</p><p>less than 24 hours before treatment with methotrexate, since blood concentrations of methotrexate may</p><p>rise and the toxicity of this substance be increase. Cases of serious toxicity have been reported when</p><p>methotrexate and NSAIDs including diclofenac are given within 24 hours of each other. This</p><p>interaction is mediated through accumulation of methotrexate resulting from impairment of renal</p><p>excretion in the presence of the NSAID.</p><p>&nbsp;</p><p><strong>Ciclosporin: </strong>Diclofenac, like other NSAIDs, may increase the nephrotoxicity of ciclosporin due to the</p><p>effect on renal prostaglandins. Therefore, it should be given at doses lower than those that would be</p><p>used in patients not receiving ciclosporin.</p><p>&nbsp;</p><p><strong>Tacrolimus: </strong>Possible increased risk of nephrotoxicity when NSAIDs are given with tacrolimus. This</p><p>might be mediated through renal antiprostagladin effects of both NSAID and calcineurin inhibitor.</p><p>&nbsp;</p><p><strong>Quinolone antibacterials: </strong>Convulsions may occur due to an interaction between quinolones and</p><p>NSAIDs. This may occur in patients with or without a previous history of epilepsy or convulsions.</p><p>Therefore, caution should be exercised when considering the use of a quinolone in patients who are</p><p>already receiving an NSAID.</p><p>&nbsp;</p><p><strong>Phenytoin: </strong>When using phenytoin concomitantly with diclofenac, monitoring of phenytoin plasma</p><p>concentrations is recommended due to an expected increase in exposure to phenytoin.</p><p>&nbsp;</p><p><strong>Colestipol and cholestyramine: </strong>These agents can induce a delay or decrease in absorption of</p><p>diclofenac. Therefore, it is recommended to administer diclofenac at least one hour before or 4 to 6</p><p>hours after administration of colestipol/ cholestyramine.</p><p>&nbsp;</p><p><strong>Cardiac glycosides: </strong>Concomitant use of cardiac glycosides and NSAIDs in patients may exacerbate</p><p>cardiac failure, reduce GFR and increase plasma glycoside levels.</p><p>&nbsp;</p><p><strong>Mifepristone: </strong>NSAIDs should not be used for 8-12 days after mifepristone administration as NSAIDs</p><p>can reduce the effect of mifepristone.</p><p>&nbsp;</p><p><strong>Zidovudine:</strong> Increased risk of haematological toxicity when NSAIDs are given with zidovudine. There is evidence of an increased risk of haemarthroses and haematoma in HIV(+) haemophiliacs receiving concurrent treatment with zidovudine and ibuprofen.</p><p>&nbsp;</p><p><strong>Potent CYP2C9 inhibitors: </strong>Caution is recommended when co-prescribing diclofenac with potent</p><p>CYP2C9 inhibitors (such as voriconazole), which could result in a significant increase in peak plasma</p><p>concentrations and exposure to diclofenac due to inhibition of diclofenac metabolism.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal</p><p>development. Data from epidemiological studies suggest an increased risk of miscarriage and or cardiac</p><p>malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The</p><p>absolute risk for cardiovascular malformation was increased from less than 1% up to approximately</p><p>1.5%.</p><p>&nbsp;</p><p>The risk is believed to increase with dose and duration of therapy. In animals, administration of a</p><p>prostaglandin synthesis inhibitor has shown to result in increased pre-and post-implantation loss and</p><p>embryo-foetal lethality.</p><p>In addition, increased incidences of various malformations, including cardiovascular, have been</p><p>reported in animals given a prostaglandin synthesis inhibitor during organogenetic period.</p><p>From the 20th week of pregnancy onward, Voltarol use may cause oligohydramnios resulting from foetal renal dysfunction. This may occur shortly after treatment initiation and is usually reversible upon discontinuation.&nbsp; In addition, there have been reports of ductus arterious constriction following treatment in the second trimester, most of which resolved after treatment cessation.&nbsp; Therefore, during the first and second trimester of pregnancy, Voltarol should not be given unless clearly necessary.&nbsp;</p><p>If Voltaren is used by a woman attempting to conceive, or during the first or second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible.</p><p>Antenatal monitoring for oligohydramnios and ductus arteriosus constriction should be considered after exposure to diclofenac for several days from gestational week 20 onward. Voltarol should be discontinued if oligohydramnios or ductus arteriosus constriction is found.</p><p>&nbsp;</p><p>During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to:</p><p>- cardiopulmonary toxicity (premature constriction/ closure of the ductus arteriosus and pulmonary</p><p>hypertension)</p><p>- renal dysfunction, (see above)</p><p>The mother and the neonate, at the end of the pregnancy, to:</p><p>- possible prolongation of bleeding time, an anti-aggregating effect which may occur even at</p><p>very low doses</p><p>- inhibition of uterine contractions resulting in delayed or prolonged labour</p><p>Consequently, Voltaren is contra-indicated during the third trimester of pregnancy.</p><p>&nbsp;</p><p><strong>Lactation</strong></p><p>Like other NSAIDs, diclofenac passes into breast milk in small amounts. Therefore, Diclefenac should</p><p>not be administered during breast feeding in order to avoid undesirable effects in the infant (see section</p><p>5.2 Pharmacokinetic properties).</p><p>&nbsp;</p><p><strong>Femaile fertility:</strong></p><p>As with other NSAIDs, the use of diclofenac may impair female fertility and is not recommended in</p><p>women attempting to conceive. In women who may have difficulties conceiving or who are</p><p>undergoing investigation of infertility, withdrawal of diclofenac should be considered. See also</p><p>section 4.4 Special warnings and precautions for use, regarding female fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients who experience visual disturbances, light-headedness , dizziness, , drowsiness,or other central nervous system disturbances while taking Voltaren should refrain from driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions are ranked under the heading of frequency, the most frequent first, using the following convention: very common: (&gt;1/10); common (&ge; 1/100, &lt;1/10); uncommon (&ge; 1/1,000, &lt;1/100); rare (&ge;1/10,000, &lt;1/1000); very rare (&lt;1/10,000); not known: cannot be estimated from available data.</p><p>&nbsp;</p><p>The following undesirable effects include those reported with other short-term or long-term use.</p><p>&nbsp;</p><p><strong>Table 1</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:606px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Thrombocytopenia, leucopoenia, anaemia (including haemolytic and aplastic anaemia), agranulocytosis.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p><p>&nbsp;</p><p>Very rare</p></td><td style="vertical-align:top"><p>Hypersensitivity, anaphylactic and anaphylactoid reactions (including hypotension and shock).</p><p>Angioneurotic oedema (including face oedema).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Disorientation, depression, insomnia, nightmare, irritability, psychotic disorder.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>Rare</p><p>Very rare</p><p>&nbsp;</p><p>&nbsp;</p><p>Unknown</p></td><td style="vertical-align:top"><p>Headache, dizziness.</p><p>Somnolence, tiredness.</p><p>Paraesthesia, memory impairment, convulsion, anxiety, tremor, aseptic meningitis, taste disturbances, cerebrovascular accident.</p><p>Confusion, hallucinations, disturbances of sensation, malaise.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p><p>Unknown</p></td><td style="vertical-align:top"><p>Visual disturbance, vision blurred, diplopia.</p><p>Optic neuritis.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>Very rare</p></td><td style="vertical-align:top"><p>Vertigo.</p><p>Tinnitus, hearing impaired.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon*</p></td><td style="vertical-align:top"><p>Myocardial infarction, cardiac failure, palpitations, chest pain.</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Kounis syndrome.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hypertension, hypotension, vasculitis.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p><p>Very rare</p></td><td style="vertical-align:top"><p>Asthma (including dyspnoea).</p><p>Pneumonitis.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>Rare</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Very rare</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Unknown</p></td><td style="vertical-align:top"><p>Nausea, vomiting, diarrhoea, dyspepsia, abdominal pain, flatulence, anorexia.</p><p>Gastritis, gastrointestinal haemorrhage, haematemesis, diarrhoea haemorrhagic, melaena, gastrointestinal ulcer with or without bleeding or perforation (sometimes fatal particularly in the elderly).</p><p>Colitis (including haemorrhagic colitis and exacerbation of ulcerative colitis or Crohn&#39;s disease), constipation, stomatitis (including ulcerative stomatitis), glossitis, oesophageal disorder, diaphragm-like intestinal strictures, pancreatitis.</p><p>Ischaemic colitis.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>Rare</p><p>Very rare</p></td><td style="vertical-align:top"><p>Transaminases increased.</p><p>Hepatitis, jaundice, liver disorder.</p><p>Fulminant hepatitis, hepatic necrosis, hepatic failure.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>Rare</p><p>Very rare</p></td><td style="vertical-align:top"><p>Rash.</p><p>Urticaria.</p><p>Bullous eruptions, eczema, erythema, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell&#39;s syndrome), dermatitis exfoliative, loss of hair, photosensitivity reaction, purpura, allergic purpura, pruritus.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Acute renal failure, haematuria, proteinuria, nephrotic syndrome, interstitial nephritis, renal papillary necrosis.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Impotence.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Application site irritation, oedema.</p></td></tr></tbody></table><p><em>* The frequency reflects data from long-term treatment with a high dose (150 mg/day).</em></p><p><em>&nbsp;</em></p><p>Clinical trial and epidemiological data consistently point towards an increased risk of arterial</p><p>thrombotic events (for example myocardial infarction or stroke) associated with the use of diclofenac,</p><p>particularly at high doses (150mg daily) and in long term treatment (see sections 4.3 and 4.4 for</p><p>Contraindications and Special warnings and special precautions for use)<em>.</em></p><p><em>&nbsp;</em></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It</p><p>allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&bull; Saudi Arabia</p><p>-The National Pharmacovigilance Centre (NPC):</p><p>o Fax: +966-11-205-7662</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp; &nbsp;&nbsp;Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms</strong></p><p>There is no typical clinical picture resulting from diclofenac over dosage. Over dosage can cause</p><p>symptoms such as headache, nausea, vomiting, epigastric pain, gastrointestinal bleeding, diarrhoea,</p><p>dizziness, disorientation, excitation, coma, drowsiness, tinnitus, fainting or convulsions. In the case of</p><p>significant poisoning acute renal failure and liver damage are possible.</p><p>&nbsp;</p><p><strong>Therapeutic measures</strong></p><p>Patients should be treated symptomatically as required. Within one hour of ingestion of a potentially</p><p>toxic amount, activated charcoal should be considered. Alternatively, in adults gastric lavage should</p><p>be considered within one hour of ingestion of potentially toxic amounts. Frequent or prolonged</p><p>convulsions should be treated with intravenous diazepam. Other measures may be indicated by the</p><p>patients clinical condition.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>ATC code: </em>M01AB05</p><p>There is a limited clinical trial experience of the use of diclofenac in JRA/JIA paediatric patients. In a</p><p>randomised, double-blind, 2-week, parallel group study in children aged 3-15 years with JRA/JIA, the</p><p>efficacy and safety of daily 2-3 mg/kg BW diclofenac was compared with acetylsalicylic acid (ASS,</p><p>50-100 mg/kg BW/d) and placebo &ndash; 15 patients in each group. In the global evaluation, 11 of 15</p><p>diclofenac patients, 6 of 12 aspirin and 4 of 15 placebo patients showed improvement with the difference</p><p>being statistically significant (p &lt;0.05). The number of tender joints decreased with diclofenac and ASS</p><p>but increased with placebo. In a second randomised, double-blind, 6 week, parallel group study in</p><p>children aged 4-15 years with JRA/JIA, the efficacy of diclofenac (daily dose 2-3 mg/kg BW, n=22)</p><p>was comparable with that of indomethacin (daily dose 2-3 mg/kg BW, (n=23).</p><p>&nbsp;</p><p>In 15 clinical studies involving the use of rectal diclofenac in the treatment of postoperative pain in</p><p>children with an overall mean age of 8 years, the use of rescue analgesia (particularly opiates) was</p><p>reduced.</p><p>&nbsp;</p><p><strong><em>Pharmacotherapeutic group</em></strong></p><p>Nonsteroidal anti-inflammatory drugs (NSAIDs).</p><p>&nbsp;</p><p><strong><em>Mechanism of action</em></strong></p><p>Voltaren is a nonsteroidal agent with marked analgesic/anti- inflammatory properties. It is an inhibitor</p><p>of prostaglandin synthetase, (cyclo-oxygenase).</p><p>Diclofenac sodium <em>in vitro </em>does not suppress proteoglycan biosynthesis in cartilage at concentrations</p><p>equivalent to the concentrations reached in human beings.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited kinetic data from 6 children aged 6-16 years with juvenile chronic arthritis who received</p><p>a once daily dose of diclofenac for 2 weeks. When corrected for a body weight of 75kg, kinetic</p><p>parameters were similar to those in adults.</p><p>&nbsp;</p><p><strong>Absorption</strong></p><p>Absorption is rapid; although the rate of absorption is slower than from enteric-coated tablets</p><p>administered orally. After the administration of 50mg suppositories, peak plasma concentrations are</p><p>attained on average within 1 hour, but maximum concentrations per dose unit are about two thirds of</p><p>those reached after administration of enteric-coated tablets (1.95 &plusmn; 0.8&mu;g/ml (1.9&mu;g/ml &equiv; 5.9&mu;mol/l)).</p><p>&nbsp;</p><p><strong>Bioavailability</strong></p><p>As with oral preparations the AUC is approximately a half of the value obtained from a parenteral dose.</p><p>Pharmacokinetic behaviour does not change on repeated administration. Accumulation does not occur,</p><p>provided the recommended dosage intervals are observed. The plasma concentrations attained in</p><p>children given equivalent doses (mg/kg, b.w.) are similar to those obtained in adults.</p><p>&nbsp;</p><p><strong>Distribution</strong></p><p>The active substance is 99.7% protein bound, mainly to albumin (99.4%).</p><p>Diclofenac enters the synovial fluid, where maximum concentrations are measured 2-4 hours after the</p><p>peak plasma values have been reached. The apparent half-life for elimination from the synovial fluid is</p><p>3-6 hours. Two hours after reaching the peak plasma levels, concentrations of the active substance are</p><p>already higher in the synovial fluid than they are in the plasma and remain higher for up to 12 hours.</p><p>Diclofenac was detected in a low concentration (100 ng/mL) in breast milk in one nursing mother. The</p><p>estimated amount ingested by an infant consuming breast milk is equivalent to a 0.03 mg/kg/day dose.</p><p>(see section 4.6 Pregnancy and lactation).</p><p>&nbsp;</p><p><strong>Metabolism</strong></p><p>Biotransformation of diclofenac takes place partly by glucuronidation of the intact molecule, but mainly</p><p>by single and multiple hydroxylation and methoxylation, resulting in several phenolic metabolites ,</p><p>most of which are converted to glucuronide conjugates. Two phenolic metabolites are biologically</p><p>active, but to a much lesser extent than diclofenac.</p><p>&nbsp;</p><p><strong>Elimination</strong></p><p>The total systemic clearance of diclofenac in plasma is 263 &plusmn; 56 mL/min (mean value &plusmn; SD). The</p><p>terminal half-life in plasma is 1-2 hours. Four of the metabolites, including the two active ones, also</p><p>have short plasma half-lives of 1-3 hours.</p><p>&nbsp;</p><p>About 60% of the administered dose is excreted in the urine in the form of the glucuronide conjugate</p><p>of the intact molecule and as metabolites, most of which are also converted to glucuronide conjugates.</p><p>Less than 1% is excreted as unchanged substance. The rest of the dose is eliminated as metabolites</p><p>through the bile in the faeces.</p><p>&nbsp;</p><p><strong>Characteristics in patients</strong></p><p>No relevant age-dependent differences in the drug&#39;s absorption, metabolism, or excretion have been</p><p>observed, other than the finding that in five elderly patients, a 15 minute iv infusion resulted in 50%</p><p>higher plasma concentrations than expected with young healthy subjects.</p><p>&nbsp;</p><p><em>Patients with renal impairment: </em>In patients suffering from renal impairment, no accumulation of the</p><p>unchanged active substance can be inferred from the single-dose kinetics when applying the usual</p><p>dosage schedule. At a creatinine clearance of less than 10 mL/min, the calculated steady-state plasma</p><p>levels of the hydroxy metabolites are about 4 times higher than in normal subjects. However, the</p><p>metabolites are ultimately cleared through the bile.</p><p>&nbsp;</p><p><em>Patients with hepatic disease: </em>In patients with chronic hepatitis or non-decompensated cirrhosis, the</p><p>kinetics and metabolism of diclofenac are the same as in patients without liver disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None stated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Voltaren suppositories also contain suppository mass 5 (a waxy base composed of hard fat).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Three years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Protect from heat (store below 30&deg;C).</p><p>Medicines should be kept out of the reach of children.</p><p>Do not use after the expiry date (= EXP) printed on the pack.</p><p>Suppositories should not be cut apart, as incorrect storage conditions may lead to uneven distribution of the active substance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The suppositories are white to yellowish, torpedo-shaped, with smooth or slightly rough surfaces and a</p><p>slightly fatty odour, and are sealed in a composite foil made of polyvinylchloride (PVC) laminated with</p><p>low-density polyethylene (LD-PE).</p><p>&bull; Voltaren Suppository 12.5 mg and 50 mg: They come in packs of 10</p><p>&bull; Voltaren Suppository 100 mg: They come in packs of 5</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For rectal use only.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com   

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02/ 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>